Objective: To compare demographics and treatment patterns for dementia patients residing in assisted living facilities (ALF) and skilled-nursing facilities (SNF). Design: Cross-sectional, retrospective chart review. Setting: Patients with dementia residing in five assisted living and six skilled-nursing facilities in Western Oregon and Tacoma, Washington. Patients: 119 assisted living and 190 SNF nursing patients with a diagnosis of dementia. Main Outcome Measures: Similarities and differences in patient demographics, underlying comorbidity, duration of disease, and treatment characteristics for dementia. Results: The analysis revealed higher prevalence of nonAlzheimer's dementia, history of cerebral vascular accident, depression, and diabetes in the SNF cohort. There were higher proportions of assisted living patients having dementia of less than one-year's duration. Low proportions of patients in both settings were receiving treatment (44% of assisted living patients and 11% of SNF), despite the finding that 78% and 62% of assisted living and SNF patients had a dementia diagnosis of less than three years. In addition, when cholinesterase inhibitors were ordered, the dosing was not fully titrated in a majority of patients. Reduction in behavioral medication use in treated ALF patients but not in treated SNF patients also was observed. Conclusion: This analysis revealed opportunities for intervention and improved treatment for patients with dementia in ALFs. There are opportunities to maximize treatment efficacy by initiating cholinesterase inhibitor medications and maximizing dose titration. To adequately quantify potential benefit of dementia treatment in SNF patients, additional studies with larger numbers of treated patients are needed.
Introduction
Alzheimer's disease (AD) affects approximately 4.5 million Americans, doubling in prevalence every four years after age 65. 1 AD frequently goes unrecognized, is misdiagnosed, and may not be addressed until the latter stages of disease. 2, 3 Pharmacologic treatment has been shown to attenuate the functional decline associated with AD, particularly when started in the early stages of disease and is effective when maximal doses of treatment agents are utilized. [4] [5] [6] Yet, lack of disease recognition or reluctance to initiate treatment in early disease stages may delay intervention until patients are less likely to achieve optimal benefit. 5, 7 Additionally, early discontinuation of treatment has been shown to culminate in a nonrecoverable functional decline. 7 As a result, early disease recognition, in conjunction with institution of therapy at a maximum tolerated dose, is critical in maximizing treatment benefit and optimally delaying disease progression. 7 Further, to maximize the benefit potential, facilitating disease awareness and managing treatment expectations are critical for patients, family members, caregivers, and providers. 8 This study was undertaken to assess similarities and differences in baseline demographics and treatment patterns of patients with dementia residing in assisted living facilities (ALF) and skilled nursing facilities (SNFs).The goal of this assessment was to identify potential areas and opportunities for future prospective interventions to optimize treatment and delay disease progression for patients with AD.
Methods
This study was a cross-sectional, retrospective analysis of patients with a diagnosis of dementia who resided in five assisted living and six SNFs from August 1, 2002, through October 31, 2002. The patients, located in Western Oregon and Tacoma,Washington, were identified by the facility consultant pharmacists through random, manual screenings of the medical record during the course of their monthly record reviews. Examination of the patient's medical record and analysis of the organization's electronic pharmacy database was conducted in patients with a diagnosis of dementia that was documented in the medical record. Information derived from the patient chart assessment consisted of: ■ Patient demographic information (age, gender) ■ Nature (type) and duration of dementia based on information provided by the patient's physician and documented in the medical record ■ Characterization of underlying comorbidities with the potential to obscure dementia diagnosis and evaluation, or reflect or significantly affect the number of medications that the patients receive on a routine basis ■ Determination and stratification of use of the most commonly accepted therapies for dementia, which at the time of assessment included three cholinesterase inhibitors (ChEIs) (donepezil, rivastigmine, and galantamine) and vitamin E.
Data Components
The following information was collected and patients were stratified on the basis of the following:
■ Age and gender collected from current physician's orders and the patient information sheet or medical record Abbrevations: CVA cerebral vascular accident, DM = diabetes mellitus, NOS = not otherwise specified, NS = not significant. 
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■ The presence or absence of the following comorbidities: arthritis, acute or chronic pain syndrome not attributable to arthritis, hypothyroidism, history of a cerebral-vascular accident (CVA), presence of diabetes, or depression ■ Estimated disease duration (as noted by the diagnosis date or first date of documentation in medical record) and nature (type) of dementia ■ The presence or absence of standard pharmacotherapy for dementia (cholinesterase inhibitor use or vitamin E), along with the type of treatment and dosage utilized ■ Presence or absence of use of other behavioral medications (antipsychotics, mood stabilizers, anxiolytics)
Upon completion of data collection, data were entered into an electronic document and de-identified; only aggregate data were kept for analysis. All original data collection materials were destroyed.
Inclusion/Exclusion Criteria
Patients were included in the analysis if they had an established, documented diagnosis for dementia and were 65 years of age or older. Patients were excluded from analysis if any of the primary endpoint information was unobtainable. Where appropriate, application of statistical assessment was conducted. Prevalence and frequency determinations were assessed using the Chi-square test; continuous, parametric data were assessed using the two-sample t-test; and nonparametric data were assessed using the Mann-Whitney, two-sample rank test.
Results
The charts of 309 patients, 119 from assisted-living facilities and 190 from skilled-nursing facilities, were reviewed. Demographic information for patients with dementia is reported in Table 1 .The average patient age was 90, and a majority of patients were female (78%). Assisted living patients had shorter duration of disease compared with SNF patients (28% versus 11% <1 yr duration; P < 0.01).
More established disease was more common, but was not significantly different in SNF patients (38% versus 22% with disease >3 yrs; P = 0.07) (Figure 1 ). Comorbidities were evenly distributed with respect to pain, arthritis, and hypothyroidism, while the prevalence of prior CVA, diabetes, and depression was significantly higher for SNF versus ALF patients ( Figure 2 ). ChEIs were utilized in 34% of ALF patients and 7% of SNF patients, while vitamin E was used in 18% and 5% of ALF and SNF patients (P < 0.001). Donepezil was the most frequent ChEI used in both treatment populations, being the agent utilized in 75% of patients receiving a ChEI, followed by rivastigmine at 19% and galantamine at 6%.The majority of patients receiving ChEIs in both ALF and SNFs were not titrated to the maximal dose (60% and 70%). Maximal dose titration was most prevalent for donepezil and least prevalent for rivastigmine.Treatment characteristics are further described in Tables 2 and 3 and Figures 3 and 4 .
In assisted-living patients, use of behavioral medications was significantly higher (P < 0.05) in the untreated cohort of patients not receiving ChEIs or vitamin E (43%), compared with the cohort receiving ChEIs alone (23%), but not significant in vitamin E-only-treated patients (32%). In SNF patients, higher behavioral medication use (62%, n = 8) was observed in patients receiving ChEIs compared with those who were not (25%, n= 43) (P < 0.05). Additional features associated with use of behavioral medications are described in Tables 4 and 5 .
Discussion
Assessment of baseline demographic information revealed that patients residing in ALFs and SNFs were evenly matched with regard to age and gender. While patients residing in SNFs tended to be older (92 versus 86 years of age), this difference did not reach statistical significance (P > 0.05). A trend toward a higher prevalence of dementia of the Alzheimer's type in ALF patients and other variants of dementia in SNF patients was observed. A greater proportion of ALF patients had new onset of dementia-with diagnosis in the last year-compared with SNF patients (P < 0.01).The proportion of patients with a dementia diagnosis ≥three-years' duration was similar for both groups (P = 0.07). SNF patients trended toward having dementia for a longer period of time than their ALF counterparts.
The number of patients treated for dementia was relatively small in both groups, but significantly higher in ALF patients compared with SNF patients (44% versus 11%, P < 0.001). A contributing factor to lower levels of treatment in SNF patients may have been a higher level of vascular risk (history of CVA and diabetes).The role and benefit of ChEIs in individuals with vascular dementia is more controversial and less-well defined, as in the use in individuals who reside in SNFs or those with more severe disease. Lack of dose titration for ChEIs was noted in both ALF and SNF patients. Often, the initial dose of an agent was ordered with no further titration initiated. In most instances, documentation for lack of titration was absent.This finding may reflect patient receipt of the maximal tolerated dose, physician preference, or oversight. Use of donepezil was most frequently associated with use of the highest relative average dose, along with highest proportion of patients receiving the maximal dose. Use of routine medications was similar in treated and untreated populations in both ALFs and SNFs.There was a trend favoring higher routine medication use in SNF patients (P < 0.05), perhaps reflecting increased underlying comorbidity in this group.
Increased use of behavioral medications was observed in untreated ALF patients not receiving ChEIs or vitamin E, compared with treated ALF patients and ALF patients receiving ChEIs alone, but not in ALF patients receiving vitamin E alone.These findings were reversed in SNF patients, with higher use of behavioral medications observed in patients treated with ChEIs compared with those patients not receiving medication for dementia. The basis for these findings and the impact of dementia treatment on behavioral medication use require further study. Assessment of behavioral medication use in SNF patients needs to be interpreted cautiously because of the small number of patients treated in this group.
Significant limitations of this observational study include: ■ Nonrandomized design and retrospective nature of this analysis a Ten patients receiving vitamin E were also receiving cholinesterase inhibitors. b Three patients on cholinesterase inhibitors were receiving multiple behavioral medications. c Increased frequency of behavioral medication use for the untreated cohort was statistically significant (P < 0.05) for all treated patients and the cohort receiving cholinesterase inhibitors.
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■ Charting and documentation inconsistencies in ALF patients, which may have limited the interpretability of findings in this patient population ■ The limited use of ChEIs in both patient subsets, but particularly in SNF patients, which may impact the ability to interpret treatment characteristics in this population.
Extraction of data from the patients' medical record in both ALF and SNF settings culminated in inconsistent retrieval of a dependable disease-staging tool, such as Mini-Mental State Examination. As a result, patients were staged based upon disease duration since initial diagnosis, which the authors gauged as the best reliable marker of disease acuity. Finally, inconsistent documentation for measures of functional status in the medical record (particularly in ALF settings) limited the ability to interpret these parameters on a consistent basis.
Conclusion
This analysis highlights several opportunities for intervention.The study revealed that the number of SNF patients with dementia who are not treated significantly outweighs those who are treated. In fact, 89% of patients with dementia in SNFs were left untreated for their dementia.The majority of residents in this study had a documented dementia diagnosis of less than three years, and treatment use was very limited. In addition, when medications were used for patients with dementia, maximal doses were not always achieved. More often than not the starting dose was ordered with no additional dosing titration and no documentation for lack of this dosing adjustment.The data were consistent, even several months after the start of the original order.
Reduced behavioral medication in ALF patients receiving ChEIs further supports treatment in this population. Interpretation of the lack of observed benefit in the SNF a One patient receiving Vitamin E was also receiving a cholinesterase inhibitor. b Four patients on cholinesterase inhibitors were receiving multiple behavioral medications. c Statistically significant increased frequency of behavioral medication use (P < 0.05) was observed in the cholinesterase inhibitor cohort (n = 13) compared with the untreated cohort (n = 169).
population could reflect that this group is more refractory to the benefits of therapy or simply be a reflection of insufficient number of patients treated to achieve interpretable results. Based on these results, there is opportunity for intervention and improved treatment for patients with dementia in ALFs.To adequately quantify potential benefit of dementia treatment in SNF patients, additional studies with larger numbers of treated patients are needed.
Consultant pharmacists are in the unique position to facilitate earlier treatment of dementia, ensure proper ChEI-dose titration, maximize dosing for each patient, and screen for development of drug-related side effects. Furthermore, consultant pharmacists should take a patient-centered approach to care, focusing beyond the medication component.The consultant pharmacist should be able to evaluate the patient to assess the level of cognitive, functional, and behavioral improvement, or stabilization while on appropriate dementia drug therapy. The pharmacist can also evaluate a patient's decline, which could reflect a lack of treatment response.
